The arthritic Paradigm
Paradigm Biopharma (ASX: PAR) listed on the ASX in August 2015. The company focuses on repurposing pentosan polysulphate sodium (PPS) and CEO Paul Rennie tells Alan Kohler Paradigm has an …
Normal CTA (3 top stocks)
Latest Posts
February 16, 2019
February 14, 2019
February 14, 2019
February 14, 2019
February 14, 2019
February 14, 2019
February 14, 2019
February 14, 2019
February 13, 2019
